Moreover, EGFR-TKI (e.g. apatinib and rapamycin) enhanced the chemosensitivity of cancer 43, 44, which suggested that anlotinib could increase the sensitivity of CRC cells to OXA. This evidence concerns the gene EGFR and colorectal carcinoma.